Magenta Therapeutics Inc Update on MGTA-117 - Corporate Call Transcript
Good day, and thank you for standing by. Welcome to the Magenta update MGTA-117. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Shan Wu, Head of Investor Relations. Please go ahead.
Thank you, operator, and good morning, everyone. Thank you for joining us today for a review of the MGTA-117 Phase I/II dose escalation clinical data that was presented at the 2022 American Society of Hematology Annual Meeting yesterday. A press release highlighting these results can be found on our website under the Investors and News section and these slides will be accessible from our website in the Events and Presentations section of the Investors & Media page after this call.
On Slide 2, the agenda for today will be our Chief Executive Officer and President, Dr. Jason Gardner, will start with an introduction. Dr. Shawn Rose, our Senior Vice President and Head of Clinical Development; and Dr. Lisa Olson, our Chief Scientific Officer, will review the highlights
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |